NCT02055157COMPLETEDanonymous

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

BMN 111

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

BMN 111

Related intelligence directories

Indication directory: Achondroplasia Modality directory: small molecule Target directory: BMN 111

Source & freshness

Source record

NCT ID

NCT02055157

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2021

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02055157

Title

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Sponsor

BioMarin Pharmaceutical

Status

COMPLETED

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BMN 111

Target normalized

BMN 111

Interventions

BMN 111

Public preview

Source record

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT02055157

Status

COMPLETED

Phase

PHASE2

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 15, 2021

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02055157

Indication

Achondroplasia

Modality

small molecule

Target

BMN 111

Intervention

BMN 111

Source record